{"id":"bat2306","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAT2306 functions as a bispecific monoclonal antibody designed to target multiple immune regulatory pathways. By engaging dual checkpoint mechanisms, it aims to overcome immune evasion and promote robust T cell activation and proliferation against tumor cells. This dual-targeting approach is intended to improve efficacy compared to single-checkpoint inhibitors.","oneSentence":"BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:35.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05377944","phase":"PHASE3","title":"Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-10-26","conditions":"Plaque Psoriasis","enrollment":502},{"nctId":"NCT04711343","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-06-08","conditions":"Psoriasis","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant human monoclonal antibody against IL-17A"],"phase":"phase_3","status":"active","brandName":"BAT2306","genericName":"BAT2306","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}